Clinical Trials Logo

Clinical Trial Summary

The hypothesis is that helical tomotherapy could minimize radiation related toxicity by avoiding or limiting doses to structures such as small bowel, external genitalia, skin, bladder, rectum, and femoral neck and head.


Clinical Trial Description

This is a phase II study using tomotherapy for radiation treatment delivery along with concurrent 5-FU/mitomycin C for the treatment of T2-T4 cancer of the anal canal. They hypothesis is that helical tomotherapy could minimize radiation related toxicity by avoiding or limiting doses to structures such as small bowel, external genitalia, skin, bladder, rectum, and femoral neck and head. This is expected to limit or reduce treatment related toxicity and hence prevent or reduce treatment breaks. This may result in delivery of radical treatment with better local control and treatment outcome than using the current radiation treatment technique at our center. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00754078
Study type Interventional
Source AHS Cancer Control Alberta
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 2008
Completion date October 2016

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05060471 - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients Phase 2
Not yet recruiting NCT03731754 - "Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection N/A
Recruiting NCT05374252 - Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients Phase 3
Recruiting NCT02185443 - Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Phase 2
Recruiting NCT05040815 - Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer Phase 2
Recruiting NCT03403465 - Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Phase 2
Active, not recruiting NCT03946358 - Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) Phase 2
Completed NCT03465501 - Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates N/A
Withdrawn NCT03942900 - Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma